This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia

This study has been completed.
Information provided by:
Henry Ford Health System Identifier:
First received: February 21, 2006
Last updated: NA
Last verified: September 2003
History: No changes posted
To study the efficacy of an antibacterial/anticoagulant solution instilled into the hemodialysis (HD) catheters after each treatment (“antibiotic lock solution - ALS”) to prevent catheter related bacteremia (CRB) and to salvage catheters with established CRB.

Condition Intervention Phase
ESRD Drug: Gentamycin/citrate, Minocycline/EDTA Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention

Resource links provided by NLM:

Further study details as provided by Henry Ford Health System:

Primary Outcome Measures:
  • Incidence of symptomatic CRB

Estimated Enrollment: 120
Study Start Date: September 2003
Estimated Study Completion Date: May 2004
  Show Detailed Description


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • ESRD patients with tunnelled catheters

Exclusion Criteria:

  • patients on IV abx for infections, patients who have AV graft, AV fistulas
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00294502

United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
Sponsors and Collaborators
Henry Ford Health System
Principal Investigator: Antanole Bearabe, MD Henry Ford Hospital
  More Information

Publications: Identifier: NCT00294502     History of Changes
Other Study ID Numbers: 3008
Study First Received: February 21, 2006
Last Updated: February 21, 2006

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 23, 2017